Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 泰格医药 |
|---|---|
| Other Market Stock Code | 300347 |
| H-Share Offer Price | HK$ 100.00 |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | Tigermed |
|---|---|
| Stock Code | 03347 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的綜合生物製藥研發服務提供商,提供臨床試驗技術服務及臨床試驗相關服務及實驗室服務,範圍涵蓋藥物和醫療器械的臨床前研究至上市後研究。 |
| Listing Date | 2020-08-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國杭州市濱江區江南大道618號東冠大廈15層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號陽光中心40樓全層 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | tigermedgrp.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | Yes (A股) |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 100.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 10,000 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2020-07-28 to 2020-07-31 |
| Global Offering Shares | 107,065,100 shares |
| HK Public Offer Shares (Initial) | 5,888,600 shares (5.5%) |
| Public Offer Lots (Initial) | 58,886lots (Pool A29,443lots,Pool B29,443lots) |
| International Placing Shares (Initial) | 101,176,500 shares (94.5%) |
| Offer Ratio | ~5.5% |
| Total Shares Post-IPO | 856,520,650 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 10,706,510,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 10,000 |
| 2 lots | 200 | HK$ 20,000 |
| 3 lots | 300 | HK$ 30,000 |
| 4 lots | 400 | HK$ 40,000 |
| 5 lots | 500 | HK$ 50,000 |
| 6 lots | 600 | HK$ 60,000 |
| 7 lots | 700 | HK$ 70,000 |
| 8 lots | 800 | HK$ 80,000 |
| 9 lots | 900 | HK$ 90,000 |
| 10 lots | 1,000 | HK$ 100,000 |
| 15 lots | 1,500 | HK$ 150,000 |
| 20 lots | 2,000 | HK$ 200,000 |
| 25 lots | 2,500 | HK$ 250,000 |
| 30 lots | 3,000 | HK$ 300,000 |
| 35 lots | 3,500 | HK$ 350,000 |
| 40 lots | 4,000 | HK$ 400,000 |
| 45 lots | 4,500 | HK$ 450,000 |
| 50 lots | 5,000 | HK$ 500,000 |
| 60 lots | 6,000 | HK$ 600,000 |
| 70 lots | 7,000 | HK$ 700,000 |
| 80 lots | 8,000 | HK$ 800,000 |
| 90 lots | 9,000 | HK$ 900,000 |
| 100 lots | 10,000 | HK$ 1,000,000 |
| 200 lots | 20,000 | HK$ 2,000,000 |
| 300 lots | 30,000 | HK$ 3,000,000 |
| 400 lots | 40,000 | HK$ 4,000,000 |
| 500 lots | 50,000 | HK$ 5,000,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 60,000 | HK$ 6,000,000 |
| 700 lots | 70,000 | HK$ 7,000,000 |
| 800 lots | 80,000 | HK$ 8,000,000 |
| 900 lots | 90,000 | HK$ 9,000,000 |
| 1,000 lots | 100,000 | HK$ 10,000,000 |
| 2,000 lots | 200,000 | HK$ 20,000,000 |
| 3,000 lots | 300,000 | HK$ 30,000,000 |
| 4,000 lots | 400,000 | HK$ 40,000,000 |
| 5,000 lots | 500,000 | HK$ 50,000,000 |
| 6,000 lots | 600,000 | HK$ 60,000,000 |
| 7,000 lots | 700,000 | HK$ 70,000,000 |
| 8,000 lots | 800,000 | HK$ 80,000,000 |
| 9,000 lots | 900,000 | HK$ 90,000,000 |
| 10,000 lots | 1,000,000 | HK$ 100,000,000 |
| 20,000 lots | 2,000,000 | HK$ 200,000,000 |
| 29,443 lots | 2,944,300 | HK$ 294,430,000 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 4.97B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 85,652,065,000 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 10,706,510,000 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣974.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue | 1,682,504 | 2,299,534 | 2,803,309 |
| Cost of sales | -969,752 | -1,318,199 | -1,511,409 |
| Gross profit | 712,752 | 981,335 | 1,291,900 |
| Other income and gains, net | 30,912 | 22,234 | 64,149 |
| Selling and distribution expenses | -39,749 | -54,454 | -81,072 |
| Administrative expenses | -239,106 | -316,423 | -350,510 |
| Operating profit | 504,664 | 772,669 | 1,140,783 |
| Net finance costs | -11,661 | -19,365 | -42,243 |
| Share of associates and JVs | -6,199 | 9,598 | -9,768 |
| Profit before tax | 486,804 | 762,902 | 1,088,772 |
| Income tax expense | -92,647 | -107,653 | -113,839 |
| Profit for the year | 394,157 | 655,249 | 974,933 |
| Profit attributable to owners | 344,977 | 576,886 | 841,247 |
Balance Sheet
| Item | 2017 | 2018 | 2019 | 2020-03 |
|---|---|---|---|---|
| Cash and cash equivalents | 14 | 519 | 1,206 | |
| Trade and bills receivables | 468,584 | 533,811 | 756,028 | |
| Inventories | 299,488 | 382,695 | 490,393 | |
| Total current assets | 1,377,281 | 1,648,740 | 3,366,314 | |
| Total assets | 3,733,074 | 4,586,604 | 7,567,976 | |
| Total current liabilities | 786,730 | 1,259,980 | 1,811,986 | |
| Total liabilities | 844,526 | 1,314,455 | 2,046,698 | |
| Total equity | 2,888,548 | 3,272,149 | 5,521,278 | |
| Equity attributable to owners | 2,555,619 | 2,828,042 | 4,246,842 | |
| Interest-bearing borrowings | 276,868 | 634,863 | 901,363 | 1,121,629 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 | 2020-03 |
|---|---|---|---|---|
| Net cash from operating activities | 308,347 | 509,373 | 537,551 | |
| Depreciation of PP&E | 27,469 | 55,648 | 50,273 | 12,134 |
| Depreciation of right-of-use assets | 46,562 | 14,454 | ||
| Amortisation of intangible assets | 4,751 | 5,492 | 7,367 | 4,395 |
| Purchase of PP&E | -49,293 | -75,815 | -88,600 | -20,328 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 113.3 |
|---|---|
| First Day Open | HK$ 119.0 |
| First Day Change | 13.30% |
| First Day Volume | 33927600.0 |
| First Day Turnover | 3926800000.0 |
| Use of Proceeds | 1、15%或約1,540.9百萬港元用于內生擴大及提升我們在臨床試驗技術服務及臨床試驗相關服務種類及能力,以滿足海外市場對我們服務不斷增加的需求;
2、40%或約4,109.0百萬港元用于作為我們全球擴張計劃的一部分,為潛在收購可補足我們現有業務的具吸引力海外臨床合同研究機構提供資金;
3、20%或約2,054.5百萬港元用于內生通過對以創新業務模式營運及具增長潛力的公司進行少數股權投資,促進我們生物制藥研發生態系統發展;
4、10%或約1,027.3百萬港元用于償還我們截至2020年5月31日的若干未償還借款;
5、5%或約513.6百萬港元用于開發及推行技術以進一步提升我們綜合服務種類的質素及效率;
6、10%或約1,027.3百萬港元用于營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (6)
Joint Bookrunners (11)
Merrill Lynch (Asia Pacific) Limited CE AAC198
海通国际证券有限公司 CE AAF806
中信证券(香港)有限公司 CE AAK249
中国国际金融香港证券有限公司 CE AEN894
UBS Securities Hong Kong Limited CE BIN466
Jefferies Hong Kong Limited CE ATS546
招银国际融资有限公司 CE AVM940
Credit Suisse (Hong Kong) Limited CE AAO017
Fosun International Securities Limited CE AAF432
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362
Joint Lead Managers (4)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 葉小平 | — |
| Company Secretary | 高峻 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 葉小平博士及曹曉春女士(一致行動人)合共持有本公司已發行股份總數約31.3%(全球發售完成後約27.4%),為控股股東。 |
|---|




